ImmunityBio Inc. (IBRX)
2.47
-0.01 (-0.40%)
At close: Apr 17, 2025, 3:59 PM
2.48
0.40%
After-hours: Apr 17, 2025, 07:58 PM EDT
-0.40% (1D)
| Bid | 2.45 |
| Market Cap | 2.18B |
| Revenue (ttm) | 14.74M |
| Net Income (ttm) | -413.56M |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -3.98 |
| Forward PE | -7.06 |
| Analyst | Buy |
| Ask | 2.51 |
| Volume | 4,342,836 |
| Avg. Volume (20D) | 6,484,719 |
| Open | 2.49 |
| Previous Close | 2.48 |
| Day's Range | 2.39 - 2.50 |
| 52-Week Range | 2.28 - 10.53 |
| Beta | -0.13 |
About IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2015
Employees 680
Stock Exchange NASDAQ
Ticker Symbol IBRX
Website https://immunitybio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 223.89% from the latest price.
Stock ForecastsNext Earnings Release
ImmunityBio Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-13.37%
ImmunityBio shares are trading lower after the com...
Unlock content with
Pro Subscription
1 month ago
+15.03%
ImmuniyBio shares are trading higher after the company announced it received FDA RMAT Designation for ANKTIVA(R) and CAR-NK.
